Clinical Trial Update: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating a combination of an immune checkpoint inhibitor for locally advanced or metastatic MSI/dMMR esogastric adenocarcinomas; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Snippet

Sponsor: Centre Leon Berard | Conditions: Gastric Cancer, MSI-H | Phase 3 | Status: RECRUITING